OmiCrohn study: choosing the right medicine with AI
Too often, people with Crohn’s disease have to switch medications because it’s impossible to predict whether their medication will work or not. Hopefully, this will change in the near future thanks to artificial intelligence (AI).
Goal
The OmiCrohn study will investigate whether a simple blood test using AI can predict which biologic drug (vedolizumab or ustekinumab) will or will not be effective in a patient with Crohn’s disease. Infliximab and adalimumab may also be added in a later phase of the study.
The research
Researchers are using an AI model that uses blood samples from people with Crohn’s disease to predict which medication will be most effective in bringing the disease into remission. Participants in the study will receive a scan at the beginning of their studies and after six months. In hospitals that already use ultrasound, patients will also receive an ultrasound scan.
There will be two study groups. In one group, the gastroenterologist will determine whether someone receives vedolizumab or ustekinumab, and in the other group, AI will determine which of these two medications someone receives.
Who can participate?
- You can participate in the study if you have had treatment with a maximum of one biological drug (adalimumab, infliximab) or a JAK inhibitor, and this did not work.
- Or if you have not yet had any treatment with a biological drug.
- Furthermore, your disease must be active, so you must experience symptoms.
An extensive list with inclusion criteria can be found on this page.
More information
- Read more about the study.
- Poster OmniCrohn with a summary of the study.
Podcast video about OmiCrohn
Participating hospitals
Interested?
Do you have Crohn’s disease and are you being treated at one of these hospitals? Do you think you meet the criteria to participate? Then ask your gastroenterologist if you can participate in the OmiCrohn study.